Prognostic correlations and response to treatment in advanced metastatic malignant melanoma.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000577:Amides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000532:radiotherapy; D002330:Carmustine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007414:Intestinal Neoplasms / Q000188:drug therapy; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008099:Liver / Q000503:physiopathology; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011877:Radionuclide Imaging; D012737:Sex Factors; D012878:Skin Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D014750:Vincristine; D003907:Dexamethasone; D007770:L-Lactate Dehydrogenase; D002330:Carmustine